The association between RCAS1 expression in laryngeal and pharyngeal cancer and its healthy stroma with cancer relapse

Dutsch-Wicherek, Magdalena; Tomaszewska, Romana; Lazar, Agata; Wicherek, Lukasz; Składzień, Jacek

doi:10.1186/1471-2407-9-35

Cited by 22 publications

(35 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This incidence of RCAS1 positivity is among the highest reported incidences for all types of head and neck malignancies, including oral and esophageal SCC [18–25]. A similar incidence of RCAS1 positivity was reported in laryngeal and pharyngeal SCC, in which RCAS1 protein was detected in all the examined tissue samples [33]. To this respect, current substantial evidence supports that RCAS1 may be considered as a promising target for future (gene) therapeutic approaches [6,17].…”

Section: Discussionsupporting

confidence: 66%

RCAS1 expression in mobile tongue squamous cell carcinoma: An immunohistochemical study

et al. 2011

View full text Add to dashboard Cite

SummaryBackgroundThe receptor-binding cancer antigen expressed on SiSo cells (RCAS1) is a human tumor-associated antigen that has been considered to play a crucial role in tumor progression by enabling cancer cells to evade immune surveillance. The present study aimed to evaluate the clinical significance of RCAS1 expression in mobile tongue squamous cell carcinoma (SCC).Material/MethodsRCAS1 protein expression was assessed immunohistochemically on 49 mobile tongue SCC tissue samples obtained from an equal number of patients and was statistically analyzed with clinicopathological characteristics and overall and disease-free patients’ survival.ResultsEnhanced RCAS1 expression was significantly associated with reduced depth of invasion (p=0.0069), low mitotic index (p=0.0251) and no evidence of muscular invasion (p=0.0098). A borderline association between RCAS1 expression and stromal inflammatory reaction was also noted (p=0.0660). RCAS1 expression was not associated with overall and disease-free survival.ConclusionsOur data support evidence for possible implication of RCAS1 at the early stage of tumor progression in mobile tongue SCC, whereas the survival prediction using RCAS1 expression as a clinical marker seems uncertain for this type of malignancy.

show abstract

Section: Discussionsupporting

confidence: 66%

RCAS1 expression in mobile tongue squamous cell carcinoma: An immunohistochemical study

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Interestingly, the results of all recently published studies are very controversial. As yet, overexpression of RCAS-1 in HNSCC has only been demonstrated in 4 independent studies in oral squamous cell carcinomas [18][19][20][21] . Toyoshima et al [20] could not demonstrate a difference in survival between patients with low and high expression of RCAS-1 whereas Tsai et al [18] and Fukuda et al [19] showed a large survival benefit for patients with low expression of RCAS-1.…”

Section: Discussionmentioning

confidence: 99%

“…Toyoshima et al [20] could not demonstrate a difference in survival between patients with low and high expression of RCAS-1 whereas Tsai et al [18] and Fukuda et al [19] showed a large survival benefit for patients with low expression of RCAS-1. Dutsch-Wicherek et al [21] examined clear surgical margins in HNSCC patients and found significantly higher levels in patients with recurrences.…”

Section: Discussionmentioning

confidence: 99%

RCAS-1 Serum and Tumor Levels in Head and Neck Squamous Cell Carcinoma

Brunner¹,

Erovic²,

Heiduschka³

et al. 2010

Eur Surg Res

View full text Add to dashboard Cite

Background/Aims: RCAS-1 is a transmembrane protein that is involved in the evasion of host immune surveillance by tumor cells. It has been found to be a valuable prognostic and diagnostic marker in a number of different malignancies. The objective of the study was to analyze the potency of RCAS-1 as a biomarker in the serum of patients with head and neck squamous cell carcinoma (HNSCC). Methods: ELISA was performed with prospectively collected serum samples from 60 patients with HNSCC (taken at the time of diagnosis, after 3 and 12 months) and from 31 healthy controls. To correlate serum levels with RCAS-1 expression in the tumor, immunohistochemical staining of RCAS-1 was done using a tissue microarray. Results: Surprisingly, median sRCAS-1 levels were basically identical between tumor patients and controls. Interestingly, patients with low RCAS-1 values at the time of diagnosis had better disease-free survival. 62% of tumor samples expressed RCAS-1 but we could not demonstrate a correlation between protein expression and serum levels. Conclusion: This study was the first to correlate RCAS-1 levels in the serum and in the tumor of the same patients. RCAS-1 seems to have prognostic properties although larger studies will be necessary to fully evaluate its role in HNSCC.

show abstract

“…Although several researchers have suggested a potential link between advanced malignancy and high-level expression of EBAG9 in tumor tissue (3,(23)(24)(25)(26)(27)(28), evidence that this molecule itself exerts an in vivo tumor-promoting function has been lacking. Recently, Ogushi et al reported for the first time that the enhanced expression of EBAG9 in Renca mouse renal cancer cells leads to accelerated in vivo cell growth, using two representative clones generated by transfection of a human EBAG9 cDNA (12).…”

Section: Discussionmentioning

confidence: 99%

Intracellular estrogen receptor-binding fragment-associated antigen 9 exerts in vivo tumor-promoting effects via its coiled-coil region

Maeyama

Otsu²,

Kubo

et al. 2011

Int J Oncol

View full text Add to dashboard Cite

Abstract. Estrogen receptor-binding fragment-associated antigen 9 (EBAG9) is a tumor-promoting factor of largely unknown function. To assess a causative role of EBAG9 in advanced malignancies, we generated the EG7-OVA and MethA murine tumor cell lines that stably express full-length or truncated EBAG9 protein, using retroviral-mediated gene transduction. Upon subcutaneous inoculation into immunocompetent mice, both cell lines showed marked acceleration of in vivo tumor growth when full-length EBAG9 was overexpressed. Interestingly, deletion of the coiled-coil region, thereby producing truncated EBAG9 protein, abolished the tumor-acceleration effect, establishing the importance of this domain in EBAG9-mediated tumor promotion. However, there was no alteration in in vitro cell proliferation or expression levels of MHC class I and co-stimulatory molecules believed to play a role in immune evasion of tumor cells in these tumor cell lines expressing full-length or truncated EBAG9 protein. Furthermore, both full-length and truncated EBAG9 proteins showed a predominantly cytoplasmic localization in the tumor cells. Collectively, these results suggest that EBAG9 overexpression can be causative in enhancing the malignant properties of tumor cells, and that tumor promotion likely requires EBAG9 intracellular association with as yet unidentified binding partners via the coiled-coil region.

show abstract

The association between RCAS1 expression in laryngeal and pharyngeal cancer and its healthy stroma with cancer relapse

Cited by 22 publications

References 25 publications

RCAS1 expression in mobile tongue squamous cell carcinoma: An immunohistochemical study

RCAS1 expression in mobile tongue squamous cell carcinoma: An immunohistochemical study

RCAS-1 Serum and Tumor Levels in Head and Neck Squamous Cell Carcinoma

Intracellular estrogen receptor-binding fragment-associated antigen 9 exerts in vivo tumor-promoting effects via its coiled-coil region

Contact Info

Product

Resources

About